For all request of viral vectors, please visit the Gene Vector Core Website or send an email to [email protected]. Since 1999, the Vector Development Laboratory has developed and implemented novel ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Leader in manufacturing reagents and critical components for biomedical research to leverage Etcembly’s AI platform to ...

The longstanding ambition of developing an inhaled gene therapy for cystic fibrosis has taken a step forward, with the start of a phase I/II trial of a product using a novel pseudotyped viral vector ...